Drugs / Interferon
Interferon
Trials 10
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon | “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗12“Interferon -IFN (3 MU/sm x 3 times/week, x 12 weeks)” NCT00842114 ↗ |
| Known as | Human interferon a2b injection | “Generic name: Human interferon a2b injection; Dosage form: solution; Dosage: 1ml: 3 million IU;” NCT05912946 ↗ |
| Known as | IFN | “Interferon -IFN (3 MU/sm x 3 times/week, x 12 weeks)” NCT00842114 ↗ |
| Known as | IFNα | “Interferon (IFNα, Roferon-A)” NCT00962715 ↗ |
| Action | Inhibit | “It can inhibit the replication and transcription of JCPyV through a variety of pathways.” NCT05912946 ↗ |
| Route | Subcutaneous | “The drug will be administered subcutaneously by the patient.” NCT00001228 ↗ |